入排依据:未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
摘要
摘要
The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and infection. The engineered graft appears to instruct immune reconstitution toward a regulated, tolerance-associated state, giving the product a mechanism for further studies. The question is how far we can further program it.
KM 提取结果
0 个 Figure · 0 个 KM 面板